The relevance of the study is due to the search for prognostically significant causes of non-developing pregnancy (NP) and the development of adequate prevention of identified disorders. Methylenetetrahydrofolate reductase encoded by the MTHFR gene determines the balance of folic acid derivatives and homocysteine (HC) / methionine. Polymorphic variants of folate genes can lead to excessive accumulation of HC in the blood and hypomethylation of DNA, which contributes to an increase in reproductive losses in early gestation. Carrying out periconceptional prophylaxis with high doses of folic acid (4000 mcg) reduces the level of free HC in the blood, but is effective only when it begins 3 months before conception and in the early stages of embryo and fetus development (up to 12 weeks). Based on the study, it was proposed to use folic acid at a dose of 4000 mcg in a high-risk group for the development of NP (pregnant women with hyperhomocysteinemia) 16 weeks before conception and 12 weeks after conception.
Read full abstract